comparemela.com

Latest Breaking News On - Anders ullman - Page 4 : comparemela.com

Changes to Sobi s management

/PRNewswire/ Anton (Tony) Hoos, M.D., Ph.D., MBA will become Head of R&D and Medical Affairs and Chief Medical Officer and replace Anders Ullman, M.D., Ph.D..

United statesNorth carolinaAnton tony hoosAnders ullmanTony hoosGuido oelkersPatient focused medicine developmentSobi investor relations teamSobi executive committeeMedical affairsChief medical officerSobi executiveSobi mediaNorth americaMiddle eastOrphan biovitrum

NEJM publishes data demonstrating clinically meaningful prevention of bleeds and superior bleed protection for efanesoctocog alfa

/PRNewswire/ Pivotal study data published in The New England Journal of Medicine (NEJM) continues to highlight the efficacy, safety, and pharmacokinetic.

United statesAnders ullmanEuropean commissionUs food drug administrationSobi investor relations teamHead of research developmentNew england journalAngela weyandAssociate professorMedical affairsChief medical officerOrphan drug designationDrug administrationBiologics license applicationNorth africaMiddle eastern

EC approves Zynlonta® for large B-cell lymphoma

Antibody drug conjugate Zynlonta can now be used in all European Union member states, Iceland, Norway and Liechtenstein.

Anders ullmanEuropean unionEuropean commissionDrug administrationHead of research developmentEuropean medicines agencyMedicinal productsHuman useMedical affairsChief medical officerAmeet mallikChief executive officer

EC approves Sobi-ADC s Zynlonta for diffuse large B-cell lymphoma

The EC has granted conditional marketing authorisation for Sobi and ADC Therapeutics’ Zynlonta to treat diffuse large B-cell lymphoma.

Anders ullmanSobi research developmentCommittee for medicinal products humanEuropean unionEuropean medicines agencyEuropean commissionDrug administrationMedicinal productsHuman useMedical affairs

Swedish Orphan Biovitrum AB: Zynlonta (loncastuximab tesirine) approved in the EU for the treatment of relapsed or refractory diffuse large B-cell lymphoma

STOCKHOLM, Dec. 21, 2022 /PRNewswire/ Sobi and ADC Therapeutics SA today announced that the European Commission (EC) has granted conditional marketing authorisation for the use of Zynlonta

United statesNew jerseyUnited kingdomCity ofLausanne biopAnders ullmanPrnewswire sobiCompany on twitterEuropean commissionDrug administrationSobi investor relations teamCommittee for orphan medicinal productsEuropean unionHead of research developmentMedicinal productsHuman use

vimarsana © 2020. All Rights Reserved.